QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 发表日期：2017    专题：合肥物质科学研究院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice 期刊论文 DIABETOLOGIA, 2017, 卷号: 60, 期号: 5, 页码: 900-910 作者:  Wu, Rong;  Sun, Jian-guang;  Wang, Ji-qiu;  Li, Binhua;  Liu, Qingsong 收藏  |  浏览/下载：14/0  |  提交时间：2018/07/26 Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model 期刊论文 SCIENTIFIC REPORTS, 2017, 卷号: 7, 期号: 无, 页码: 1-10 作者:  Wu, Hong;  Huang, Qiong;  Qi, Ziping;  Chen, Yongfei;  Wang, Aoli 收藏  |  浏览/下载：39/0  |  提交时间：2018/07/04 Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl5-(3,4,5-trimethoxybenzamido)phenyI)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 5, 页码: 1793-1816 作者:  Liang, Xiaofei;  Lv, Fengchao;  Wang, Beilei;  Yu, Kailin;  Wu, Hong 收藏  |  浏览/下载：724/0  |  提交时间：2018/07/04 Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode 期刊论文 ONCOTARGET, 2017, 卷号: 8, 期号: 11, 页码: 18359-18372 作者:  Hu, Chen;  Wang, Aoli;  Wu, Hong;  Qi, Ziping;  Li, Xixiang 收藏  |  浏览/下载：44/0  |  提交时间：2018/07/04 Egfr  Egfrt790m  Nsclc  Kinase Inhibitors  Drug Resistance   Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations 期刊论文 CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29 - 收藏  |  浏览/下载：4/0  |  提交时间：2020/10/26 EGFR MUTATIONS  GEFITINIB TREATMENT  1ST-LINE TREATMENT  OPEN-LABEL  RARE  MULTICENTER  ERLOTINIB  GENE  CHEMOTHERAPY  EFFICACY  Non-small cell lung cancer  EGFR  uncommon mutation  target therapy